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Saprophytic and thermophilic moulds of Aspergillus species are ubiquitary opportu-
nistic fungi commonly isolated from immunocompromised individuals with acute leu-
kemia, transplant recipients, patients with autoimmune diseases, and AIDS patients; these
fungi are the major cause of high morbidity and mortality (1). In the immunocompetent
host, Aspergillus species could colonize lung residual cavities or injured airways (i.e.,
cystic fibrosis, tuberculosis, sarcoidosis). The most common clinical manifestation of in-
fection by Aspergillus species is invasive aspergillosis with mortality higher than 90%. A.
fumigatus, A. flavus, A. niger and A. terreus are frequently isolated from airways (nose,
throat, bronchi) of such patients, and colonization could lead to invasive aspergillosis.
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Clinical isolates of fifty strains of A. fumigatus and 30 stra-
ins of A. flavus from immmunocompromised patients from
the hematological unit were analyzed for mycotoxin pro-
duction and compared with the same number of environ-
mental isolates (from soil, compost, and air). Only 9 (18%)
strains of A. fumigatus produced gliotoxin in a mean con-
centration 2.22 mg mL–1 (range 0.5–5 mg mL–1). Aflatox-
in B1 was detected in 7 (23%) isolates (range from 0.02 to
1.2 mg L–1) and aflatoxin G1 in one (3%) of clinical A.
flavus isolates (0.12 mg L–1). In the group of environmen-
tal isolates, 11 (37%) were positive for aflatoxin B1 pro-
duction (range from 0.02 to 1.2 mg L–1) and one for afla-
toxin G1 (0.02 mg L–1). Bioautoantibiogram (»bioassay in
situ«) on TLC plates against Bacillus subtilis NCTC 8236
showed that only gliotoxin-producing strains have bac-
tericidal activity of Rf values corresponding to gliotoxin.
The secondary-metabolite profiles of clinical and environ-
mental A. fumigatus and A. flavus isolates were homogene-
ous, except for gliotoxin production, which was detected
only in the group of clinical isolates of A. fumigatus (18%).
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Pathogenesis of aspergillosis is dependent on various factors of the host (immune
status) and virulence factors of the pathogen. Except for the physical factors of fungi,
such as their ability to grow at the temperature and pH of host tissues and small size of
conidia (2), some putative virulence factors have been identified for different Aspergillus
species. These include adhensins, pigment-secreted hydrolytic enzymes such as proteases,
phospholipases, ribonucleases, restrictocin; production of catalases, superoxide-dismu-
tases and production of the mycotoxins, low-molecular-weight, non-protein metabolites
(3–5). One of the mycotoxins produced by A. fumigatus and A. terreus strains is gliotoxin,
while aflatoxins are produced by A. flavus. These toxins could play a significant role in
the pathogenesis of invasive aspergillosis. Gliotoxin is produced in vivo in tissues of ani-
mals infected with A. fumigatus (6–9), and it was recently detected in sera of patients
with invasive aspergillosis (8).
Gliotoxin is a potent immunosuppressive mycotoxin and belongs to the epipoly-
thiodioxopiperazine family with an active disulfide bridge in its structure. In the in vitro
assays, gliotoxin inhibits phagocotosis by thymocytes, macrophages, induction of cyto-
toxic T cells, and stimulation of lymphocytes with mitogen (11). Gliotoxin can undergo
redox cycling, generating oxygen radicals that cause oxidative damage to isolated DNA
and induce apoptosis (12, 13).
Aflatoxins (AFB1, AFB2, AFG1, AFG2, AFM1) are mycotoxins produced by A. flavus,
A. parasiticus and A. nomius strains. Aflatoxins also show a wide range of immunotoxic
effects, they depress phagocitosis, intacellular killing and spontaneous superoxide pro-
duction of macrophages (14–16). Aflatoxin B1 also inhibits the production of the tumor-
-necrosis factor  (TNF), interleukin-1 (IL-1) and IL-6 by lipopolysaccharide-stimulated
macrophages (17).
Recent studies suggest that there are differences between clinical and environmen-
tal isolates of A. fumigatus strains in the activity of phospholipase (18). The ability of in
vitro production of mycotoxins, aflatoxin B1, G1 and sterigmatocystin by the A. fumigatus
and A. versicolor strains isolated from surgically removed tissues of patients with pulmo-
nary asperegilloma (19) induced us to check out the possibility of mycotoxin production
of A. fumigatus and A. flavus strains isolated from immunocompromised patients, and to
compare its production with environmental isolates.
EXPERIMENTAL
Reagents and solvents
Gentamicin, streptomycine sulphate, penicillin G, polisorbate 80, Czapek-Dox salts
(MgSO4 x 7 H2O, NaNO3, KH2PO4, KCl and FeSO4), AgNO3, AlCl3 x 6 H2O and triphenyl-
-tetrazolium chloride were purchased from Fluka, Germany. Anhydrous Na2SO4, chloro-
form, ethyl acetate, formic acid and ethanol (96%, V/V) were purchased from Kemika
(Croatia).
Microbiological media, Sabouraud 2% (m/V) glucose agar, Müller-Hinton agar, yeast
extract and sucrose were purchased from Merck (Germany).
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Gliotoxin standard was purchased from Calbiochem, Germany and aflatoxins from
Sigma, USA.
All solvents used were of analytical grade.
Isolation and cultivation of mould isolates
Fifty strains of Aspergillus fumigatus Fresenius and thirty strains of Aspergillus flavus
Link were recovered from immunocompromised patients with various diseases from the
Hematological unit. Moulds were recovered from swabs at 25 ± 2 °C on Sabouraud
2%-glucose agar (SGA) with 50 mg L–1 gentamicin. Environmental isolates of fifty A.
fumigatus strains and thirty A. flavus strains were isolated from the soil (compost) and air
using SDA with 50 mg L–1 streptomycin and 20.000 I.U. of penicillin G, after incubation
at 37 ± 1 °C for 72 h. A. fumigatus and A. flavus strains were identified according to their
cultural and microscopic characteristics on Czapek agar and SGA at 37 ± 1 °C (20, 21).
After primary isolation, strains were kept on SGA slants at –20 °C.
At the time of analysis, the conidia were harvested from a 5-day-old culture at 37 ±
1 °C by adding 5 mL of sterile physiological saline containing 0.05% polysorbate 80 (Twe-
en® 80) to each SDA slant. The culture was scraped with a loop and 1 mL suspension,
containing approximately 1–5 x 107 conidia/mL, was used for cultivation on the me-
dium for biosynthesis.
Cultivation on yeast-extract liquid medium for biosynthesis
All isolates of A. fumigatus and A. flavus strains were grown on yeast-extract liquid
medium (YES) containing yeast extract 20 g, sucrose 40 g and distilled water to 1000 mL.
YES medium was sterilized by autoclaving for 15 minutes at 121 °C. Erlenmayer flasks
(250 mL) with 50 mL of YES were inoculated with 1 mL of 1–5 x 107 conidia suspension.
Flasks were than incubated six days at 25 ± 2 °C. Flasks were shaken periodically.
Extraction and mycotoxin analysis
The biomass was washed with 50 mL of chloroform and cut up into small pieces
with a mixer at 3.500 rpm. The biomass was then filtrated through a Whatman No. 1 fil-
ter paper and extracted using 2 x 25 mL of chloroform, and filtrated through anhydrous
Na2SO4. Chloroform fraction was pooled and evaporated to dryness on a rotary evapo-
rator at reduced pressure and at 60 °C. For gliotoxin quantification, dried extracts were
dissolved in 500 µL of chloroform and stored at 4 °C until analysis. Detection of glio-
toxin was performed using a combination of methods by Bauer et al. (6) and Land et al.
(22) using thin-layer chromatography (TLC). TLC plates were used (20 x 20 cm, 0.25 mm
thickness, Silica Gel Merck 60 GF with fluorescence indicator 254 nm) for the detection
of gliotoxin and aflatoxins from biosynthesis in developing solvents toluene/ethyl ace-
tate/formic acid, 5:4:1 (V/V/V). For gliotoxin visualization at UV 366 nm, developed pla-
tes were sprayed with 10% (w/V) aluminium chloride in 50% (V/V) ethanol and heated
10 minutes at 110 °C. Gliotoxin appeared as a bluish-green spot under UV 366 nm at Rf
value 0.59. Another method was used to prove gliotoxin when plates were sprayed with
367
I. Kosalec and S. Pepeljnjak: Mycotoxigenicity of clinical and environmental Aspergillus fumigatus and A. flavus isolates, Acta Pharm.
55 (2005) 365–375.
freshly prepared 10% (m/V) silver nitrate in 80% (V/V) ethanol. Gliotoxin then appeared
as a brown spot in visible light at Rf value 0.59. Aflatoxins appeared as blue (aflatoxin
B1), and green (aflatoxin G1) spots under UV 366 nm with or without spraying with 10%
(w/V) aluminium chloride in 50% (V/V) ethanol at Rf values at 0.59 (B1) and 0.66 (G1).
In certain cases, two-dimensional TLC (20 x 20 cm) was used for confirmation of the
detected mycotoxins.
Gliotoxin and aflatoxins were semi-quantitatively analyzed on TLC plates compar-
ing of the fluorescence under UV 366 nm of gliotoxin from extracts and the fluorescence
of gliotoxin standard solution (or standard solution of aflatoxins) after developing and
spraying the plates with 10% (m/V) aluminium chloride in 50% (V/V) ethanol and heat-
ing for 10 minutes at 110 °C.
Bioautoantibiogram on thin-layer chromatography plates against Bacillus subtilis
For localization of bactericidal compounds from extracts in the biosynthesis after se-
paration by TLC, plates were left 3 days at room temperature (mobile phase evaporated
completely). TLC surface was sprayed with sterile physiological saline and 15 mL of
Müller-Hinton agar melted at approximately 50 °C and inoculated with 1 mL of the sus-
pension of Bacillus subtilis NCTC 8236 cells (107 CFU mL–1) was poured on the surface.
The inoculated plates were stored in a humid atmosphere, and incubated overnight at 37
± 1 °C. The zone of inhibition around compounds separated from extracts was visua-
lized by spraying the bioautography-plates with 1% (m/V) triphenyl-tetrazolium chlo-
ride (TTC) solution in sterile distilled water. Only living bacterial cells hydrolyzed TTC
to red colored formazan. The zone of growth inhibition was clearly visible around the
bactericidal compound on the TLC plate.
Statistical analysis
Concentrations of gliotoxin and aflatoxins were calculated as mean ± SE. Numbers
of metabolites from environmental and clinical isolates were compared by the t-test fol-
lowing the Mann Whitney U post-test using the GraphPad Prism Software, GraphPad
Software, San Diego, CA.
RESULTS AND DISCUSSION
Cultivation in YES liquid medium and mycotoxins production analysis
Most of the clinical strains of Aspergillus fumigatus and A. flavus were isolated from
immunosuppressed patients with acute leukemia: twenty-seven (54%) of 50 clinical A.
fumigatus strains and seventeen (56%) of 30 A. flavus strains. The other A. fumigatus and
A. flavus strains were isolated from patients with Hodkgin’s and non-Hodkgin’s diseas-
es, liver and heart operations, and other diseases listed in Tables I and II.
All of 100 A. fumigatus isolates were analyzed by thin-layer chromatography (TLC)
for gliotoxin production.
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Only 9 strains (18%) of A. fumigatus from the group of clinical isolates produced
gliotoxin after 6 days of incubation in YES liquid medium at 25 ± 2 °C. Gliotoxin pro-
ducing strains were isolated from patients with leukemia (5 isolates), and other strains
from patients undergoing heart surgery (2 isolates), and one isolate each from patients
with Hodgkin’s disease and non-Hodgkin’s disease (Table I). Semi-quantitative analysis
of gliotoxin concentration in YES liquid medium showed that the concentration of glio-
toxin depended on the A. fumigatus strain and ranged from 0.5 to 5 mg mL–1, with the
mean concentration of 2.22 mg mL–1.
Apart from gliotoxin production in 9 strains, fifteen different metabolites were iso-
lated and visualized on developed TLC plates from the chloroformic extract of A. fu-
migatus culture in YES liquid medium. Rf values of these metabolites in clinical and en-
vironmental isolates are presented in Fig. 1.
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Table I. Source of clinical isolates of A. fumigatus strains
Isolate codea Diagnosis Number of isolates
6407, 6409, 6410, 6412, 6449, 6387, 6388, 6391,
6394, 6397, 6403, 6404, 6459, 6460, 6462, 6464
Myeloid leukemia 16
6392, 6396, 6398, 6398B, 6408, 6413, 6414,
6434, 6434B, 6448, 6458
Lymphatic leukemia 11
6400, 6402, 6406, 6411, 6460B, 6467 Hodgkin’s disease 6
6395, 6405, 6415, 6386, 6389 Heart surgery 5
6393, 6463, 6465 Non-Hodgkin’s disease 3
6390, 6457, 6466 Bronchopneumonia 3
6399, 6401 Liver transplantation 2
6470, 6470B Plasmacytome, lung embolia 2
6445 Aplastic anemia 1
6468 Chronic sinusitis 1
Total 50
a The isolation code is the number of fungal strains from the Collection of Microorganisms of the Depertment
of Microbiology, Faculty of Pharmacy and Biochemistry, University of Zagreb.
Table II. Source of clinical isolates of A. flavus strains
Isolate codea Diagnosis Number of isolates
6417, 6419, 6420, 6421, 6435, 6435B, 6438,
6449, 6449B, 6453, 6454, 6613, 6613B
Myeloid leukemia 13
6416, 6418, 6436, 6437, 6455, 6612 Hodgkin’s disease 6
6434, 6439, 6441, 6609 Lymphatic leukemia 4
6390, 6607, 6607B Heart surgery 3
6451, 6453, 6611 Non-Hodgkin’s disease 3
6440 »Immunodeficiency« 1
Total 30
a The isolation code is the number of fungal strains from the Collection of Microorganisms of the Department
of Microbiology, Faculty of Pharmacy and Biochemistry, University of Zagreb.
None of 50 environmental A. fumigatus isolates produced gliotoxin, nor did any of
the examined 60 A. flavus strains. No production of aflatoxins in A. fumigatus strains was
detected either.
Incidence of these metabolites in groups of clinical and environmental isolates was
compared, and no statistic difference was recorded. Analysis of secondary metabolites
indicates homogenic distribution in both groups of A. fumigatus isolates.
Sixty strains of A. flavus were examined for aflatoxins production. After 6 days at 25
± 2 °C eleven of the 30 environmental strains (37%) produced aflatoxin B1 in a concen-
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Fig. 1. Frequency of 16 separated secondary metabolites (with Rf values from 0.08 to 0.97) on
TLC plates between clinical and environmental isolates of A. fumigatus strains (gliotoxin is







































Fig. 2. Frequency of 9 separated secondary metabolites (with Rf values from 0.31 to 0.97) on
TLC plates between clinical and environmental isolates of A. flavus strains (aflatoxins are
marked, all other metabolites are unknown).
tration from 0.024 to 1.2 mg L–1. In one of the 30 strains aflatoxin G1 production was also
detected in a concentration of 0.02 mg L–1. Similar concentration was detected in the
group of clinical isolates of A. flavus strains. Seven of the 30 strains (23%) produced afla-
toxin B1 in concentrations from 0.02 to 1.2 mg L–1. One isolate produced also aflatoxin
G1 in a concentration of 0.12 mg L–1. Concentrations of aflatoxin B1 in clinical and envi-
ronmental isolates were compared, but no differences were found. The number of me-
tabolites from chloroformic extracts of A. flavus strains in YES liquid medium at 25 ± 2
°C was compared. Six different metabolites, besides aflatoxins, were found in extracts.
Analysis of the frequency of metabolites showed no differences between clinical and en-
vironmental isolates. They had a homogenic distribution of metabolites as did the ex-
tracts from A. fumigatus strains (Fig. 2).
Antibacterial activity of metabolites using the bioautoantibiogram assay
After the TLC analysis of gliotoxin and aflatoxins, other TLC plates were used for
the bioautography assay against Bacillus subtilis NTCT 8236. In the group of clinical A.
fumigatus isolates, only gliotoxin producing strains had a clear zone of inhibition around
the Rf value of gliotoxin (Fig. 3). No zones were noticed on TLC plates with separated
metabolites in chloroformic extracts from environmental isolates of A. fumigatus strains
or in any A. flavus strains tested. For confirmation of inhibition zones corresponding to
gliotoxin, the chloroformic solution of gliotoxin (50 g mL–1) was used.
Aspergillosis is a serious opportunistic infection that can occur in immunosuppres-
sed patients. Despite the development of new antifungal drugs which may lower the in-
cidence of Aspergillus infections in transplant patients, mortality of patients with leuke-
mia and AIDS due to such infections is still very high (> 90%) (23). Aspergillosis is most
commonly caused by the fungi A. fumigatus, A. flavus, A. niger and A. terreus. These fungi
can produce low-molecular-weight secondary metabolites such as gliotoxin (A. fumiga-
tus and A. terreus) and aflatoxins (A. flavus), and the connection between mycotoxin pro-
duction in situ and the pathogenicity of aspergillosis is still unknown. It could be hy-
pothesized that the production of potent toxic metabolites of asperille such as gliotoxin
and aflatoxins at the site of mycosis could potentially play a significant role in the pa-
thogenesis of aspergillosis and other fungal diseases. Although gliotoxin is secreted in
infected tissues of man and animals, by A. fumigatus and the yeast Candida albicans, no
research has been done to find the differences between mycotoxin production by isolates
of strains colonized in airways of immunocompromised patients and environmental iso-
lates from soil and air.
In a study of Aufauvre-Brown et al. (24), a difference in virulence was found be-
tween clinical and environmental isolates in an immunosupresed mouse model and clin-
ical isolates were more virulent. Authors also suggest that these differences could be due
to the inter-mouse variation and immunossuppresion rather than to differences in viru-
lence of A. fumigatus strains. In another study, the in vitro comparison of extracellular
phospholipases (high-molecular-weight secreted metabolites) secretion of clinical and
environmental isolates showed stronger activity of phospholipases in clinical isolates of
A. fumigatus strains (18). Hobson (25) discussed the inhibition of human neutrophil pha-
gocytosis by the spore diffusates from A. fumigatus and A. terreus. In this study, spore
diffusates, which do not contain mycotoxins such as gliotoxin or other secondary metab-
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olites, inhibited phagocitosis from 89.7 to 94.6%, and equivalent inhibitory effects were
found for both clinical and environmental isolates of A. fumigatus.
Our study compares the production of secondary metabolites in vitro of clinical and
environmental A. fumigatus isolates and we found no differences in the number of me-
tabolites. The secondary-metabolites profiles were homogenous, without a significant
difference in production. A small, but significant number (9 out of 50.18%) of clinical A.
fumigatus isolates, mainly from patients with leukemia, produced gliotoxin in an aver-
age concentration of 2.22 mg mL–1 in YES liquid medium after 6 days of incubation. The
same results were found for the mycotoxin production ability of clinical and environ-
mental isolates of A. flavus strains. Similar concentrations of aflatoxins B1 and G1 were
found in both groups.
This is in agreement with earlier observations that environmental isolates do not
produce gliotoxin or produce it less frequently than other metabolites. For example,
Land et al. (22) found no gliotoxin producing strains in 100 isolates of A. fumigatus from
sawmills, but other mycotoxins such as fumitremorgen B and verruculogen were de-
tected in 32% of strains using biosynthesis in YES medium. Tep{i~ et al. (26) detected
verruculogen in 40% of A. fumigatus isolates from a saltern, and less frequently other
metabolites. Gliotoxin was not detected in 50 strains of A. fumigatus. The same results
were obtained by Fischer et al. (26), who did not detect gliotoxin in A. fumigatus strains
isolated from air around a compost facility. It is interesting that gliotoxin can be identi-
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Fig. 3. Bioautoantibiogram (»bioassay in situ«) on TLC plates against Bacillus subtilis after spraying
with TTC (Legend: S – start, F – front, 6460 – extract of A. fumigatus strain 6460, ST – standard
solution of gliotoxin 50 ng mL–1, Gtx – Rf values of developed gliotoxin, ZI – growth inhibition
zones).
fied in building materials (spruce wood, gypsum boards, chipboards) when these mate-
rials are contaminated with A. fumigatus (27).
In the tissues infected with A. fumigatus or the yeast Candida albicans, most of the
isolated strains produce gliotoxin. For example, in women with vaginitis caused by C.
albicans, 32 of 50 isolates produce gliotoxin (28), and Bauer et al. (6) detected gliotoxin in
a bovine udder infected with A. fumigatus. In recent studies of Lewis et al. (10) gliotoxin
was detected in the sera of patients with invasive aspergillosis, which indicates that glio-
toxin, and probably other mycotoxins, are produced in vivo.
Our results showed that a small number (18%) of A. fumigatus strains isolated only
from immunocompromised patients produce gliotoxin in vitro. Higher percent of afla-
toxigenic A. flavus strains was recorded in groups of environmental and clinical isolates,
37 and 23%, respectively.
After developing TLC plates, isolated metabolites from chloroformic extracts were
analyzed for antibacterial activity against Bacillus subtilis NCTC 8236. Only extracts with
gliotoxin showed inhibition zones around the Rf value of gliotoxin (Fig. 3). Other ex-
tracts of A. fumigatus and A. flavus strains had no active antibacterial metabolites, which
indicates that the bioautoantibiogram (»bioassay in situ«) on developed TLC plates aga-
inst B. subtilis is suitable for detection of gliotoxin in extracts, or that it could be used as
the confirmation assay for the presence of gliotoxin in combination with TLC.
It is known that the genetic factor of fungi and environmental conditions (substrate
composition with precursors of mycotoxins, pH of the substrate, O2/CO2 ratio) could
play an important role in mycotoxin production. The production and possible toxic ef-
fects of mycotoxins in infected tissues should be investigated, as well as the secreted
concentration and biotransformation of these metabolites. Besides gliotoxin and aflatox-
ins, the in situ production of other low-molecular-weight metabolites of Aspergillus spp.
isolated from immunosuppressed patients is in progress in our laboratory.
CONCLUSIONS
In this study we presented the in vitro production of toxic secondary metabolites –
mycotoxins from the culture of Aspergillus fumigatus and A. flavus strains isolated from
immunocompromized patients without invasive aspergillosis. Results of mycotoxin pro-
duction, including gliotoxin and aflatoxin B1 and G1, were compared with the environ-
mental isolates (from soil). The secondary-metabolite profiles of clinical and environ-
mental A. fumigatus and A. flavus isolates were homogeneous, except for the gliotoxin
production, which was detected only in the group of clinical isolates of A. fumigatus
(18%). The few, but significant gliotoxinogenic A. fumigatus strains could contribute to
the invasiveness of gliotoxin-producing A. fumigatus of A. terreus strains. From the epi-
demiological point of view, even our study was limited to the in vitro production of
mycotoxins; further studies have to compare the Apergillus strains that cause invasive
aspergillosis in immunocompromised patients, because the source of spores is the envi-
ronment. The answer to the virulence of clinically important Aspergillus strains must in-
clude secondary metabolites with toxic activity against the host’s cells and immunity
and other factors of fungi independent of the factors of compromised hosts.
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S A @ E T A K
Mikotoksinogenost klini~kih i okoli{nih Aspergillus fumigatus i A. flavus sojeva
IVAN KOSALEC i STJEPAN PEPELJNJAK
Analizirana je mikotoksinogenost pedeset klini~kih sojeva vrste A. fumigatus i tri-
deset sojeva vrste A. flavus izoliranih iz imunokompromitiranih ispitanika u hemato-
lo{kom odjelu. Kao usporedba, izoliran je isti broj okoli{nih sojeva iz zemlje, komposta i
zraka. Utvr|eno je da samo 9 sojeva (18%) vrste A. fumigatus tvori gliotoksin sa sred-
njom vrijedno{}u 2,22 mg mL–1 (u rasponu od 0,5 do 5 mg mL–1). Tvorba aflatoksina B1
utvr|ena je u 7 sojeva (23%) (raspon od 0,024 do 1,2 mg L–1) i u jednog klini~kog izolata
(3%) A. flavus vrste (0,12 mg L–1). U skupini okoli{nih sojeva utvr|ena je tvorba afla-
toksina B1 u 11 sojeva (37%) (u rasponu od 0,024 do 1,2 mg L–1) i u jednog soja tvorba
aflatoksina G1 (0,024 mg L–1). Bioautoantibiogramom na tankoslojnoj kromatografskoj
plo~i s bakterijskom vrstom Bacillus subtilis NCTC 8236 utvr|eno je da samo gliotoksi-
nogeni sojevi pokazuju baktericidnu aktivnost oko Rf vrijednosti koja odgovara gliotok-
sinu. Profili sekundarnih metabolita klini~kih i okolo{nih sojeva A. funmigatus i A. flavus
vrsta su bili homogeni, osim za tvorbu gliotoksina koji je utvr|en samo u skupini kli-
ni~kih izolata A. fumigatus sojeva (18%).
Klju~ne rije~i: Aspergillus, A. fumigatus, A. flavus, gliotoksin, aflatoksin, mikotoksin, tvorba in vitro,
sekundarni metaboliti, plijesni
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